Jean-Marc Bellemin compensation by year
IOVANCE BIOTHERAPEUTICS Summary Compensation Table · all 6 fiscal years held| Component | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Salary | $22,212 | $450,000 | $500,000 | $527,500 | $551,238 | $277,454 |
| Bonus | $130,000 | $0 | $180,000 | $47,475 | $0 | $0 |
| Stock awards | $0 | $899,899 | $0 | $0 | $2,557,873 | $379,688 |
| Option awards | $4,418,700 | $0 | $1,254,758 | $836,258 | $0 | $0 |
| Non-equity incentive | $0 | $162,000 | $240,000 | $284,850 | $124,029 | $0 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 | $0 |
| All other | $0 | $11,600 | $12,200 | $13,200 | $14,800 | $5,962 |
| Total | $4,570,912 | $1,523,499 | $2,186,957 | $1,709,283 | $3,247,940 | $663,104 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: IOVANCE BIOTHERAPEUTICS, INC. DEF 14A filed April 28, 2026, accession 0001104659-26-050458, and prior-year filings.
How this page was built: the IOVANCE BIOTHERAPEUTICS, INC. filed document, accession 0001104659-26-050458. Every figure is read from that document and cited to the page and table it appears in. Filed April 28, 2026.
Equity holdings
unvested awards at FY2022 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| Option | 50,003 | — | $50.26 |
| Option | 135,000 | — | $15.49 |
Per the Outstanding Equity Awards at Fiscal Year-End table in IOVANCE BIOTHERAPEUTICS, INC.'s FY2022 proxy; value at the fiscal year-end close, as the company printed it.
IOVANCE BIOTHERAPEUTICS’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Daniel Kirby | Chief Commercial Officer | $2,160,595 |
| Frederick Vogt | Interim Chief Executive Officer and President, General Counsel | $1,888,175 |
| Corleen Roche | Chief Financial Officer | $1,455,979 |
| Raj Puri | Chief Regulatory Officer | $1,341,778 |
| Igor Bilinsky | Chief Operating Officer | $1,118,062 |
| Matthew Rosinack | Interim Principal Financial Officer and Principal Accounting Officer | $782,491 |
| Jean-Marc Bellemin · this page | Former Chief Financial Officer | $663,104 |
Jean-Marc Bellemin's compensation dossier, IOVANCE BIOTHERAPEUTICS
You have read Jean-Marc Bellemin's totals and holdings. The dossier adds each equity grant IOVANCE BIOTHERAPEUTICS disclosed for Jean-Marc Bellemin and IOVANCE BIOTHERAPEUTICS's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.
See an example →The full IOVANCE BIOTHERAPEUTICS compensation record
free company briefThis page is one person within IOVANCE BIOTHERAPEUTICS's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the IOVANCE BIOTHERAPEUTICS proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order IOVANCE BIOTHERAPEUTICS's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are IOVANCE BIOTHERAPEUTICS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.